Welcome back to the Oncology Brothers podcast! In this episode we are joined by Dr. Neena Vijayvergia from Fox Chase Cancer Center to discuss the latest highlights from ASCO 2026, focusing on gastrointestinal (GI) studies.

We discussed key studies:

EMERALD-3 in HCC: Exploring the findings on combining TACE with Durvalumab and Tremelimumab, and the implications for patient outcomes.
FIGHT-302 in Cholangiocarcinoma: The potential of FGFR inhibitors in frontline settings and the challenges of biomarker testing.
CIRCULATE Update: The role of ctDNA in stage 2 colon cancer and how it influences treatment decisions.
MATTERHORN Update: Benefits of perioperative chemotherapy and the importance of maintaining treatment regimens for better patient outcomes.

We also touched on the evolving landscape of GI malignancies and the significance of multidisciplinary approaches in treatment planning.

Tune in for an informative discussion that aims to enhance your understanding of the latest advancements in oncology and their practical applications in the clinic.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

⁠X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to subscribe for more updates on treatment algorithms, challenging cases, and conference highlights!

#ASCO2026, #GIOncology, #ctDNA, #FGFRinhibitor, #OncologyBrothers

ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN

Oncology Brothers: Practice-Changing Cancer Discussions

ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN